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Because previous reports have suggested that digitalis
administration may lead to increased mortality after hos-
pital discharge for acute myocardial infarction, the in-
dependent importance of digitalis therapy in long-term
prognosis after acute myocardial infarction was inves-
tigated by analyzing 1,599 patients after definite myo-
cardial infarction. After hospital discharge, mortality
rate for the entire group at 4 months was 7.7% and after
1 year 14.2%. At discharge, 36.6% of the patients were
taking digitalis. Compared with those not taking digi-
talis, those taking digitalis had more historical risk fac-
tors and a higher incidence of important clinical prog-
nostic variables during the hospitalization. Their cardiac
mortality rate after 4 months and 1 year (12.5 and 22.4%,
respectively) was significantly higher than that of pa-
The use of digitalis in patients with acute myocardial in-
farction has been controversial (1-4). It has been reported
(5) that digitalis does not increase the sensitivity of the heart
to arrhythmias in the majority of patients with acute myo-
cardial infarction. An increase in the size of infarction after
digitalis administration was suspected in one study (6), but
was not confirmed later in patients with a large infarction
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tients not taking digitalis (5.0 and 9.6%, respectively).
Mortality was higher for patients taking digitalis whether
or not they had congestive heart failure during hospi-
talization. However, in a multivariate Cox analysis for
1 year outcome, neither digitalis nor any other medi-
cation variable displaced the important clinical variables
of age, congestive heart failure during the hospitaliza-
tion, previous myocardial infarction, maximal heart rate
during the hospitalization and previous angina. Quini-
dine and digitalis at discharge were selected sixth and
seventh (not significant) by the analysis.
It is concluded that digitalis therapy at discharge after
myocardial infarction was not an independent predictor
of late mortality in these patients.
and low ejection fraction (7). The long-term benefits of
digitalis therapy in patients with chronic congestive heart
failure and sinus rhythm have also been controversial (8-10).
However, recently a randomized study (1) demonstrated
that long-term digoxin therapy is beneficial for patients with
heart failure unaccompanied by atrial fibrillation, particu-
larly if a third heart sound is present.
Toxic reactions to long-term digitalis therapy (12) have
raised the suspicion of a negative influence of this drug on
mortality. An independent adverse prognostic contribution
of digitalis to mortality after acute myocardial infarction has
been described (13) using retrospective data to show a 30%
increase in mortality rate after 4 months in patients taking
digitalis who had congestive heart failure and complex ven-
tricular arrhythmias after adjustment for other relevant char-
acteristics. Also, the 1 year mortality rate after acute myo-
cardial infarction was reported in a preliminary retrospective
study (14) to be independently increased by digitalis ther-
apy. However, a recent report from the Coronary Artery
Surgery Study registry (15) showed that digitalis therapy
was not an independent risk factor in patients in whom
follow-up was started within 2 months after acute myo-
cardial infarction.
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To determine whether digitalis therapy independently af-
fects mortality after acute myocardial infarction ideally would
require an appropriately constructed prospective, random-
ized clinical trial. Whether such a trial is ever conducted
will be importantly influenced by the results of retrospective
studies. The purpose of this study was to examine in a
sizable, multicenter patient group whether there is evidence
that digitalis therapy at discharge in an independent predictor
beyond relevant clinical variables for death or survival within
the first year after acute myocardial infarction.
Methods
Patients. The study group consisted of I ,599 patients
discharged after definite acute myocardial infarction. The
diagnosis of acute myocardial infarction was established by
at least two of the following criteria: 1) characteristic chest
pain, 2) electrocardiographic changes with evolution of Q
waves (transmural infarction), and 3) elevation of serum
creatine kinase. Nontransmural infarction was diagnosed by
typical ST segment and T wave changes accompanied by
at least criterion 3. All patients were admitted to the hospital
within 24 hours after onset of symptoms, and there were
no further eligibility restrictions.
Data concerning these patients were available from a data
base maintained by the Specialized Center of Research
(SCaR) for Ischemic Heart Disease at University of Cali-
fornia, San Diego, Medical Center. The patients were re-
cruited during 1969 to 1982 from the University of Cali-
fornia, San Diego, Medical Center, during 1978 to 1982
from the San Diego Veterans Administrations Hospital, dur-
ing 1978 to 1982 from the United States Naval Regional
Medical Center, San Diego, and during 1977 to 1982 from
the Vancouver General Hospital, British Columbia, Canada.
Patients were entered into the study in a consecutive manner,
but not all patients agreed to enter the study and personnel
were not always available to enter patients. However, there
is no apparent reason to suspect a selection bias. Over half
of all eligible patients from these centers were utilized, and
examination of coronary care units registers showed the in-
hospital mortality for the patients studied and those not
studied to be the same.
Data collection. The four hospitals were all part of a
cooperative prospective study with rigid data-gathering
specifications and common data-gathering forms. Data be-
fore 1978 for the University of California, San Diego, Med-
ical Center and Vancouver General Hospital were gathered
on a different, more extensive set of forms, but according
to the same procedures. Data were gathered by a research
nurse, clinical data were checked by a research physician
and all data were screened by computer for completeness
and consistency before final entry into the data base. The
physician collaborator from Vancouver General Hospital
(H.H.) had previously been one of the main participants in
the initial years of the study at the University of California,
San Diego, Medical Center.
Clinical variables. Our methods of data acquisition and
definitions of variables have been reported in detail previ-
ously (16). Historical characteristics, physical findings and
electrocardiographic, radiographic and laboratory variables
from the entire hospitalization were assessed.
The data base was examined univariately for variables
that were related to mortality and had a higher incidence of
occurrence for patients taking digitalis. Seventeen historical
and clinical factors were identified. Age, sex, cigarette
smoking, family history of ischemic heart disease before 60
years of age, previous hypertension, diabetes, chronic ob-
structive pulmonary disease, congestive heart failure, typ-
ical angina pectoris and previous myocardial infarction were
recorded on admission. During the entire hospitalization
period, we included the maximal heart rate recorded, min-
imal systolic blood pressure recorded, pulmonary venous
congestion on any chest X-ray film defined as previously
described (17), congestive heart failure (at least two of the
following: persistent bibasilar [or higher] rales, third heart
sound, pulmonary venous congestion on X-ray film), an-
terior localization of infarction, ventricular arrhythmias (fre-
quent ventricular premature beats [more than six per min-
ute], ventricular tachycardia [more than three consecutive
ventricular premature beats] or ventricular fibrillation) and
atrial fibrillation.
In a subgroup of 432 patients, 24 hour ambulatory
electrocardiographic monitoring was performed before hos-
pital discharge. Complex ventricular arrhythmias were de-
fined as frequent ventricular premature beats (more than 1
per minute or 30 per hour), multiform ventricular premature
beats, couplets, early ventricular premature beats (R on T
phenomenon) or ventricular tachycardia (more than three
consecutive ventricular premature beats). This test was not
performed routinely in our study patients before 1978. It
has been our policy to obtain a 24 hour Holter monitor
whenever possible since that time, but only about half of
our patients have been so studied. Lack of a sufficient num-
ber of monitors has been the main obstacle. There were no
systematic selection criteria for which patients were mon-
itored; rather, monitoring was subject to equipment avail-
ability, and the incidence of risk variables in this patient
subset was similar to that in the entire group.
Discbarge medication variables. Certain variables con-
cerning medications at hospital discharge were selected a
priori for analysis. Because digitalis is generally given to
patients with congestive heart failure, it was important to
assess this potential interaction. It has been reported that
quinidine increases the blood level of digitalis (18,19), so
this interaction was also explored. In addition, it might be
expected that patients being treated with digitalis and di-
uretic drugs might have low potassium blood levels. There-
fore, the medication variables analyzed included: digitalis
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at discharge, digitalis alone (with neither quinidine nor di-
uretic drugs), digitalis and no congestive heart failure during
hospitalization, digitalis and congestive heart failure,
congestive heart failure and no digitalis, neither digitalis
nor congestive heart failure, digitalis and diuretic drugs,
digitalis and quinidine, diuretic drugs alone (without digi-
talis) and quinidine alone (without digitalis).
Follow-up. Among the 1,599 patients, 1,424 were eli-
gible and had been followed up 4 months after infarction
and 1,300 after 1 year. The mean follow-up time was 322
days. Follow-up in our prospective data base is 98.7% at 1
year. Before 1978, 1 year follow-up was about 94%. We
routinely contact patients by telephone at 3,6 and 12 months.
Thus, patients not yet contacted at 6 months had been con-
tacted at 3 months.
Information on actual medication status was obtained at
follow-up. Among patients discharged on digitalis therapy,
78% were still using digitalis at 4 months and 76% at 1
year. Among patients discharged without digitalis, 14% had
digitalis therapy initiated within 4 months and 12% were
taking digitalis after 1 year. Because the degree of crossover
was relatively small, we analyzed the effects of discharge
medication status on mortality up to 1 year.
Information on deaths was obtained from the death cer-
tificate or hospital charts in most cases. For some patients,
telephone interviews with the personal physician and family
members were obtained to clarify details. Only deaths due
to cardiac causes were included in the analyses.
Statistical analysis. Univariate statistical analyses by
chi-square or t tests were utilized to assess differences in
characteristics between patients receiving digitalis therapy
and those who were not and for studying the influence of
medication variables on mortality. To evaluate the inde-
pendent importance of prognostic variables, we used the
stepwise multivariate Cox regression model (20) available
in the Biomedical Computer Programs package of statistical
programs (21). This analysis can include patients with in-
complete follow-up whose time of survival is known, so
that all 1,599 patients could be studied. In the stepwise
model, the final number of variables is determined by a
criterion of significance.
We report on the variables selected, along with their order
of selection, regression coefficients and constants (which
can be used to calculate a prognostic score and risk) and
special chi-square values showing the significance of their
contribution to the model.
To determine whether medication variables had inde-
pendent value beyond clinical variables, we performed two
analyses. First, the Cox analysis was used to select variables
from among the clinical factors. Then the important clinical
factors were retained, and the Cox analysis was further
utilized to select additional factors from among the medi-
cation variables and the interactions we considered important.
To test the prognostic schemes, resubstitution was carried
out on the original patient population. In this procedure, a
prognostic score is first calculated for each patient in the
population (sum of each selected variable multiplied by its
regression coefficient plus a constant). Predicted risk of
death is then calculated using a baseline survival function
for the entire population provided by the program:
Risk of death 0:= 1 - baseline survival function exp (score).
Patients with a predicted risk of death greater than 10%
were classified into the high risk group for death. At 4
months, 1,424 patients could be so classified because their
status was known at least 4 months after their acute myo-
cardial infarction; at 1 year, 1,300 patients could be clas-
sified. Correct prediction was evaluated by calculating cor-
rectly classified deaths (sensitivity for prediction of death),
correctly classified survivors (specificity for prediction of
survival) and total correct prediction (accuracy of predic-
tion). In addition, the proportion of patients in the high risk
group was calculated and the predictive value assessed (mor-
tality in high risk group).
Results
Digitalis use and basic characteristics. The character-
istics of patients who were or were not taking digitalis at
the time of hospital discharge are presented in Table 1. The
incidence of digitalis therapy varied among the four hos-
pitals, with the incidence at the San Diego Veterans Admin-
istration Hospital and the University of Califomia, San Diego,
Medical Center being similar at about 50% and that at the
United States Naval Regional Medical Center in San Diego
and Vancouver General Hospital at about 30%.
Patients taking digitalis had a higher incidence of his-
torical findings that were predictive of increased risk, namely,
a higher age, more smoking, previous infarctions, angina
and congestive heart failure. Also, during the hospitalization
these patients had a higher incidence of anterior site of
infarction, congestive heart failure and pulmonary venous
congestion on chest X-ray film. In addition, patients re-
ceiving digitalis who had ambulatory electrocardiographic
monitoring exhibited a higher incidence of complex ven-
tricular arrhythmias than did patients not receiving digitalis.
Diuretic drugs and quinidine were administered more fre-
quently to patients taking digitalis. Overall mortality rate
was significantly higher for patients discharged while re-
ceiving digitalis therapy (13 versus 5% at 4 months and 22
versus 10% at 1 year). This was true within each hospital
with the exception of the United States Regional Medical
Center where mortality rate was not significantly higher for
patients discharged while receiving digitalis therapy (Table
1).
Univariate analysis. The absence of both congestive
heart failure and digitalis at discharge was a very favorable
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Table 1. Percent of Basic Characteristics for Patients With and Without Digitalis at Discharge
Patients Patients
With Without
Digitalis (%) Digitalis (%)
Total (n) 585 (37) 1014 (63)
USVASD 60 (50) 60 (50)
UCSD 198 (48) 214 (52)
USNRMC 56 (29) 140 (71)
VGH 271 (31) 600 (69)
Age (mean ± SD) (yr) 66 ± 12 59 ± 12
Men 71 77
Previous history
Infarction 35 19
Angina 49 34
Hypertension 41 34
Congestive heart failure 25 3
Diabetes 17 12
Cigarette smoking 60 73
Digitalis at admission 30 4
Diuretic drugs at admission 26 II
Hospitalization
Anterior localization 44 34
Congestive heart failure 75 41
Pulmonary congestion 62 37
Heart rate > 80 beats/min 31 61
Atrial fibrillation 25 6
Predischarge ambulatory monitoring
Data available (n = 432) 32 24
Any VPB 82 67
Complex VPB 49 31
Discharge medication
Diuretic drugs 47 13
Quinidine 29 9
Mortality after discharge
4 months overall 13 5
USVASD 17 4
UCSD 12 5
USNRMC 7 5
VGH 12 5
I year overall 22 10
UCVASD 35 14
UCSD 24 9
USNRMC 10 II
VGH 20 9
Chi-square
(t = 11.1)
6.7
49.8
36.5
6.7
173.0
9.9
27.6
230.0
57.9
16.1
163.5
90.3
77.6
118.3
14.0
11.6
14.5
230.0
5.0
24.8
5.4
7.3
0.3
11.5
34.8
5.4
5.4
0.2
15.2
A chi-square value of greater than 3.84 corresponds to a two-tailed p < 0.05. A t statistic greater than 1.96 also has this interpretation. SD =
standard deviation; UCSD = University of California, San Diego, Medical Center; USNRMC = United States Naval Regional Medical Center, San
Diego; USVASD = United States Veterans Administration Hospital, San Diego; VGH = Vancouver General Hospital; VPB = ventricular premature
beats. Figures in parentheses indicate percent.
prognostic variable (Table 2), with a 2.8% mortality rate at
4 months and 6.7% at 1 year compared with 11 and 19%,
respectively, for patients taking digitalis or with congestive
heart failure, or both (significant difference). The presence
of congestive heart failure during hospitalization in patients
not receiving digitalis at discharge also implied a signifi-
cantly higher rate of mortality compared with patients with-
out congestive heart failure (that is, 8.1 versus 2.8% at 4
months). The combination of digitalis and diuretic drugs
did not produce a significantly higher mortality rate com-
pared with digitalis alone. The addition of quinidine to dig-
italis did not increase mortality significantly.
Multivariate analysis. Four month mortality. The clin-
ical variables selected by the Cox analysis are presented in
Table 3. Age and maximal heart rate during the hospital-
ization were the most important. When medication variables
were added to the analysis (right portion of Table 3) only
two additional variables were selected, the combination of
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Table 2. Mortality at 4 Months and I Year Related to Discharge Medication Variables Using Univariate Analysis
Total
Deaths at 4 Months
Total
Deaths at I Year
Group (no.) No. (%) Group No. (%)
Total 1,424 110 (7.7) 1,300 184 (14.2)
No heart failure and no 534 15 (2.8)*t 487 33 (6.7)*t
discharge digitalis
No heart failure and 132 12 (9.1) 118 17 (14.4)*
discharge digitalis
Heart failure and no 370 30 (8.1)t 349 47 (l3.5)t
discharge digitalis
Heart failure and 388 53 (13.7)* 346 87 (25.1)*
discharge digitalis
Discharge digitalis 520 65 (12.5)* 464 104 (22.4)*
Discharge digitalis alone 196 20 (10.2) 170 30 (17.6)*
Discharge digitalis and 250 38 (15.2)* 225 57 (25.3)*
diuretic drugs
Diuretic drugs alone 118 14 (12.9) III 18 (16.2)
Discharge digitalis 151 16 (10.6) 139 37 (26.6)*
and quinidine
Quinidine alone 84 II (13.1) 78 15 (19.2)
*Indicates significant difference (p < 0.05) between patients with the characteristic compared with all others. tIndicates significant differences between
groups adjacent and below. Heart failure indicates congestive heart failure during hospitalization.
no digitalis therapy and no congestive heart failure and
administration of quinidine alone. The combination variable
was selected first (negative correlation) and discharge quin-
idine alone (without digitalis) was fifth. The six previously
selected clinical variables were retained in almost the same
order.
The lower section of Table 3 shows the resubstitution
results. No difference in correct classification of death or
survival could be detected between using clinical variables
alone and with medication variables added. Both sets of
variables produced a high risk group for death, consisting
of about 25% of the patients with approximately a 19% 4
month mortality rate (predictive value).
One year mortality. Two discharge medication variables,
quinidine alone (without digitalis) and digitalis, were se-
lected as the last two variables (sixth and seventh, respec-
tively) (Table 4). However, the chi-square value for digitalis
was not significant.
Table 3. Selected Variables and Prediction in Cox Analysis for 4 Month Mortality
Clinical Variables Alone Medication Variables Added
Variables
Age
Maximal heart rate
Pulmonary venous congestion
Previous infarction
Minimal systolic pressure
Previous heart failure
No failure, no digitalis
Quinidine alone
Constant
Baseline survival function
Classification
Total
Death
Survival
High risk group
Predictive value
Order Entry
I
2
3
4
5
6
Total No.
1,424
110
1,314
Coefficient
0.042
0.017
0.636
0.443
-0.013
0.468
-3.198
0.948
No. Correct
1,005
69
1,074
378
Chi-square
33.8
25.3
13.8
8.2
4.1
3.7
(%)
(70.6)
(62.7)
(81.7)
(26.5)
(18.3)
Order Entry
2
3
6
4
7
8
I
5
Coefficient
0.040
0.017
0.459
0.416
-0.013
0.485
-0.554
0.823
-2.800
0.952
No. Correct
1,118
69
1,027
356
Chi-square
21.3
16.1
5.7
7.7
3.8
3.6
32.6
6.6
(%)
(77.0)
(62.7)
(78.2)
(25.0)
(19.4)
No failure indicates absence of congestive heart failure during hospitalization.
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Table 4. Selected Variables and Prediction in Cox Analysis for I Year Mortality
Clinical Variables Alone Medication Variables Added
Variables Order Entry Coefficient Chi-square Order Entry Coefficient Chi-square
Age I 0.035 41.0 I 0.033 41.0
Congestive heart failure 2 0.612 25.0 2 0.556 25.0
Previous infarction 3 0.487 18.5 3 0.447 18.5
Maximal heart rate 4 0.013 13.5 4 0.012 13.5
Previous angina 5 0.423 7.1 5 0.420 7.7
Quinidine alone 6 0.731 4.0
Digitalis 7 0.292 2.8
Constant -3.984 -3.844
Baseline survival function 0.900 0.902
Classification Total No. No. Correct (%) No. Correct (%)
Total 1,300 765 (58.8) 894 (58.5)
Death 184 142 (77.2) 143 (77.8)
Survival 1,116 623 (55.8) 617 (55.3)
High risk group 635 (48.8) 642 (50.1)
Predictive value (22.4) (22.3)
Again, the classification results were almost identical for
clinical variables alone and with medication variables added
(lower section of Table 4). Correct classification of death
was very high after I year (77 to 78%) but correct classi-
fication of survivors was lower (55 to 56%), resulting in
lower total correct classification compared with the predic-
tion at 4 months. The high risk group included 50% of the
patients with a 22% 1 year mortality rate.
Role of ambulatory electrocardiographic monitoring.
The subgroup of patients who had Holter monitoring was
classified into four categories, those with and without
congestive heart failure during the hospitalization and those
with and without complex ventricular arrhythmias (Table
5). At 4 months, in each of the four categories there was a
tendency for the mortality rate to be higher in patients taking
digitalis, but it was significant only for patients with heart
failure and without complex ventricular arrhythmias (16.1
versus 2.3%, p < 0.02). The mortality rate was only slightly
higher for patients taking digitalis in the group with both
congestive heart failure and complex ventricular arrhythmias
compared with that for patients not taking digitalis (14.8
versus 12.0%, respectively).
The same tendency was present at 1 year for three of the
four categories, with a higher mortality rate in patients tak-
ing digitalis and with heart failure but without arrhythmias.
Again, this difference was significant only in patients with
heart failure without arrhythmias. The mortality rate in the
group with congestive heart failure and complex ventricular
arrhythmias not taking digitalis was 40% compared with
39% for patients with congestive heart failure and complex
arrhythmias taking digitalis (Table 5).
Multivariate analysis of subgroup with ambulatory
electrocardiographic monitoring. Only two variables,
maximal heart rate and previous history of heart failure,
entered when clinical variables, including complex arrhyth-
mias on Holter monitoring, were considered alone for mor-
tality at 4 months (Table 6). When medication variables
were also allowed to enter, discharge digitalis and quinidine
alone (without digitalis) were the first two variables to enter,
with maximal heart rate and a history of previous infarction
entered next as variables three and four followed by diuretic
drugs alone (without digitalis) as variable five. The percent
of deaths correctly identified is higher for the analysis that
includes medication variables, but the high risk group was
also larger yielding a predictive value (17.3%) identical to
that from the analysis utilizing clinical variables alone.
For mortality at 1 year, the results of the Cox analyses
were the same, regardless of whether medication variables
were allowed to enter (Table 7). A history of previous heart
failure, age and the combination of complex arrhythmias
on Holter monitoring and congestive heart failure were the
only variables selected. It is interesting to note that the
predictive value (45.1 %) is about twice as high for the
comparable analysis in the entire study group (22.4%).
Discussion
This study indicates that patients who are being treated
with digitalis at hospital discharge have a higher mortality
rate than those not receiving digitalis up to I year after acute
myocardial infarction. On univariate analysis, mortality was
increased in patients taking digitalis, regardless of the pres-
ence or absence of congestive heart failure during the hos-
pitalization. It was clear that patients taking digitalis had a
greater incidence of important prognostic variables than did
patients not taking digitalis (Table I) and, therefore, it was
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Table 5. Mortality in Relation to Digitalis at Discharge, Congestive Heart Failure During Hospitalization and Complex Ventricular
Arrhythmias From Ambulatory Monitoring
Congestive Heart Failure
Variables
Complex
Arrhythmias
Absent
Absent
Complex
Arrhythmias
Present
4 Month Mortality
Complex
Arrhythmias
Absent
Present
Complex
Arrhythmias
Present
Digitalis absent
No.
Death
(%)
Digitalis present
No.
Death
(%)
Digitalis absent
No.
Death
(%)
Digitalis present
No.
Death
(%)
90
5
(5.6)
24
3
(12.5)
70
8
(11.4)
21
4
(19.0)
27
o
18
2
(11.1 )
I Year Mortality
23
2
(8.7)
16
3
(18.8)
43 25
1 3
(2.3)* (12.0)
56 54
9 8
(16.1) (14.8)
34 IS
3 6
(8.8)* (40.0)
40 41
II 16
(27.5) (39.0)
*Statistical difference for patients with and without digitalis (p < 0.05).
important to adjust for these variables by multivariate anal-
ysis. The Cox analysis results indicate that mortality in
patients taking digitalis can for the most part be explained
by other variables such as age, previous myocardial infarc-
tion and congestive heart failure, which contain more prog-
nostic information than do the medication variables. The
only exception in the multivariate analysis was the 4 month
outcome in the subgroup with 24 hour ambulatory electro-
cardiographic monitoring. Unfortunately, ambulatory mon-
itoring was not available in all of our patients. The selection
of patients appeared to be random, however, because the
incidence of variables was similar to that in the entire group
of patients. Nevertheless, bias is always possible. Also, the
number of deaths by 4 months in this subgroup was small
Table 6. Selected Variables and Prediction in Cox Analysis for 4 Month Mortality for Patients With 24 Hour
Ambulatory Monitoring
Clinical Variables Alone Medication Variables Added
Variables Order Entry Coefficient Chi-square Order Entry Coefficient Chi-square
Maximal heart rate I 0.022 7.3 3 0.017 3.3
Previous heart failure 2 1.064 6.6
Digitalis 1 1.561 9.8
Quinidine alone 2 1.561 6.4
Previous infarction 4 0.640 3.2
Diuretic drugs alone 5 1.205 2.9
Constant - 2.233 -2.711
Baseline survival function 0.935 0.950
Classification Total No. No. Correct (%) No. Correct (%)
Total 337 257 (76.3) 238 (70.6)
Death 31 13 (41.9) 18 (58.1)
Survival 306 244 09.7) 220 (71. 9)
High risk group 75 (22.2) 104 (30.9)
Predictive value (17.3) (17.3)
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Table 7. Selected Variables and Prediction in Cox Analysis for I Year Mortality for Patients With 24 Hour Ambulatory Monitoring
0.012 4.6 3 0.012
- 1.850 -1.850
0.863 0.863
No. Correct (%) No. Correct
202 (77.7) 260
23 (43.4) 23
179 (86.5) 179
51 (19.6) 51
(45.1)
Variables
Previous heart failure
Holter arrhythmias and
failure
Age
Constant
Baseline survival function
Classification
Total
Death
Survival
High risk group
Predictive value
Order Entry
I
2
3
Total No.
260
53
207
Clinical Variables Alone
Coefficient
0.926
0.684
Chi-square
14.3
7.4
Order Entry
1
2
Medication Variables Added
Coefficient
0.926
0.684
Chi-square
14.3
7.4
4.6
(%)
(77.7)
(43.4)
(86.5)
(19.6)
(45.1)
(31 deaths) so that the results of this multivariate analysis
should be evaluated cautiously.
Variations in digitalis use in this study. In this mul-
ticenter study, clinical practice regarding digitalis therapy
differed among the participating hospitals (Table 1). The
patients seen at the United States Naval Regional Medical
Center include many on active duty and as a group they are
considerably younger and have less history of cardiac dis-
ease. The overall mortality at both 4 and 12 months is less
than for the other hospitals and appears independent of dig-
italis therapy. Even though the incidence of digitalis therapy
at discharge was lower for patients at the Vancouver General
Hospital, the mortality for patients using and not using dig-
itals was similar to that of patients at the University of
California, San Diego, Medical Center. The overall 1 year
mortality was highest for patients at the San Diego Veterans
Administration Hospital, and this was reflected in patients
both with and without digitalis therapy. The multivariate
analyses were repeated including the particular hospital it-
self as a variable, but this was not selected, indicating that
more important prognostic information is provided by the
clinical variables.
Effect of patient compliance. It is necessary to consider
patient compliance in assessing the impact of digitalis ther-
apy. We found that over 75% of the patients discharged
while being treated with digitalis continued digitalis therapy
up to 1 year after hospitalization and that 12% of patients
not taking digitalis at discharge were using this medication
at 1 year. However, we did not measure digitalis blood
levels at follow-up, nor was it possible to obtain precise
medication information at the time of death. The effects of
this degree of crossover on our analyses would be difficult
to assess. Therefore, we can present only the prognostic
importance of being discharged on digitalis therapy.
Effect of quinidine. It has been reported (18,19) that
addition of quinidine increases the blood level of digitalis.
However, we could not detect a significantly higher mor-
tality rate in patients discharged while taking both digitalis
and quinidine compared with those discharged while taking
digitalis alone. Furthermore, the combination variable was
not selected by the multivariate analysis, whereas quinidine
alone (without digitalis) was selected.
Comparison with previous studies. Our results are in
contrast to two previous studies (13,14) but in agreement
with a recent report (15), although it is difficult to compare
the reports because of differences in methods and study
patients. Moss et al. (13) used multiple logistic regression
in 812 patients, with mortality at 4 months as the end point.
Digitalis was especially important for patients with conges-
tive heart failure and complex ventricular arrhythmias on
ambulatory electrocardiographic monitoring. In this group
of patients, the predicted mortality rate difference due to an
independent contribution of digitalis and adjusted for non-
digitalis risk variables was 30%. In no other group of pa-
tients was digitalis associated with higher mortality. In our
subgroup of patients who had ambulatory monitoring, dig-
italis use appeared to influence mortality in all categories
except patients with congestive heart failure and complex
ventricular arrhythmias (Table 5). This difference was sta-
tistically significant in patients with heart failure and without
complex arrhythmias. In the patients with congestive heart
failure and complex ventricular arrhythmias, the I year mor-
tality rate was 40% in patients not taking digitalis and was
not increased further in patients taking digitalis (39%).
Bigger et at. (14) in a preliminary report, used multiple
logistic regression analysis in 490 patients followed up for
1 year. After controlling for complicating clinical variables,
digitalis therapy was reported to be significantly associated
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with cardiac death, mostly in patients with left ventricular
failure or ventricular arrhythmias. An independent prog-
nostic contribution of digitalis was suggested.
In both studies just discussed, the ratio of mortality rates
for patients receiving digitalis at discharge compared with
those not receiving digitalis (odds ratio) was 3.7 for both 4
months (13) and I year (14). In our study, the odds ratio
was only 2.6 for 4 month mortality rate and 2.2 for I year
mortality. It is possible, therefore, that because the strength
of association in these other studies was higher, multivariate
analysis might show some independent contribution of dig-
italis to mortality, whereas our study did not.
Ryan et at. (15) recently reported results from a Cox
analysis of data in 1,592 patients with acute myocardial
infarction within 2 months before entry into the Coronary
Artery Surgery Study registry. This group of patients, there-
fore, is different from those of the two previous studies
(13,14) and our study because deaths early after discharge
are excluded. The odds ratio for the 4 year mortality rate
was 3.6. In agreement with our findings, digitalis therapy
could not replace clinical variables. These included the pres-
ence of edema, left ventricular wall motion score at cardiac
catheterization, number of vessels diseased, age and pres-
ence of rales. When these variables were taken into account,
the survival curves for patients with and without digitalis
were identical up to 4.5 years after entry to the study (15).
Although angiographic variables were considered in addi-
tion to more easily obtainable clinical variables in the study
of Ryan et aI., we achieved the same conclusions for the I
year mortality rate using clinical variables alone.
Conclusions. Although patients taking digitalis have a
higher mortality rate after acute myocardial infarction, dig-
italis therapy is not an independent prognostic factor for
long-term mortality when associated clinical variables are
considered. Although digitalis was selected as a predictor
in the 4 month analysis in the subpopulation with Holter
electrocardiographic monitoring, the number of patients in
this group was relatively small. Prediction of death or sur-
vival at I year after acute myocardial infarction by multi-
variate analysis is the same whether or not medication vari-
ables, including digitalis, are utilized in the analysis.
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